Mechanisms of Action of Dimethyl Fumarate in Relapsing MS

Trial Profile

Mechanisms of Action of Dimethyl Fumarate in Relapsing MS

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 23 Jul 2016

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Jul 2016 Status changed from recruiting to withdrawn prior to enrolment.
    • 07 Apr 2016 Planned End Date changed from 1 Jan 2019 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top